Member Info for Diversified

I don’t think the ‘large Pharma contract’ will be to far away. With the UK labs to open in the next few weeks, nothing like marking an official opening date with a contract. I believe the timing of today’s announcement is fitting with the expected rollout.

Press launch audio webcast

For me, still one of the best webcasts in the last 12 months. October interims:

https://webcast.openbriefing.com/angle/

Remember the last webinar with proactive 2 weeks ago, it was reasonable to conclude that no questions had been asked to date.

On the 21st feb, 10 trading days, 150 days is up.

Given the number of peer reviewed papers proving its concept and value, I.e. the leading cancer centers globally, the probability is extremely low.

With the same FDA members evaluating Parsortix from inception 5 years ago, I think they would simply just have to answer further questions. With the primary end point from the clinical trials passed, also set up at the request of the FDA its not I matter of if but when.

Worst case, we have a business in lab services and assays that will soon more than justify today’s market cap alone, and some.

Diagnostics is very different to therapeutics in terms of risk, with all in-vitro applications since 2018 being approved.

Large Pharma Pd-l1 contract next as suggested by last webinar with proactive. That’s the commercial revenue generating RNS we all want it be part of.

No doubt we are at the business end of several years of hard work by the company:

- Lab services contracts
- Assay tests within new UK/US labs
- Sample to answer Parsortix upgrade
- Ovarian Cancer trial and then assay by year end
- FDA De Novo approval
- Several Partnership discussion in train
- Nasdaq listing
- Continued peer review publications

What a year to come, what massive catalysts this company has to look forward to. Then considering the multiple multi billion opportunities that this presents, it comes as no surprise that liquid biopsy companies have raised $5b in the last 2 years, been subject to M&A multi billion activity and its peers are worth upwards of $2b and arguably are less advanced than AGL.

Mind blowing potential, and the RNS’s will open up the eyes of the market.

All for £184m, with a rise from a low base as a result of a Jupiter dump, many will overlook an incredible opportunity. My opinion, the fun hasn’t even started yet.

The most recent estimated market size of $130b annually only accounts for 1/3rd of global opportunity.

Would be happy with 1% of this opportunity, let alone more.

At what point do we think the market will wake up to the idea that Parsortix is not just about FDA approval?

With the lab services soon to open which can generate multi million revenue, then moving onto the assays which have sensitivity and specificity 3x higher than the competitions, or in some instances meeting unmet needs, becoming a business in its own right. After all the assays are billion dollar opportunities.

An RNS should open the markets eyes to the true potential rerating to unfold.

On the 11th January American presentation AN said that the labs would open in UK within 1/2 months. He said the US lab would open March/April.

We then had the uk presentation on the 22nd January where AN said the ealry Pharma contract services would be announced shortly.

These updates and hopefully PD-L1 assay will be updated to market imminently. PD-L1 in itself is a $b market.

I think the market respects that this is a class II de novo application for a diagnostic tool which poses no risk to health unlike therapeutics. As such it’s risk profile is significantly lower and that applications in this category have historically had a very high 90%+ success rate for In-vitro applications.

With the peer reviewed papers demonstrating Parsortix as superior to the only exciting Fda approved device Cellsearch, in addition to ctDNA. We have significant evidence over and above the breast cancer and ovarian trials.

Throw into the mix we have had the same FDA case manager who is now reviewing the De Novo application for the last 5 years and we also submitted a Q submission. Like many others, I would say approval is a formality.

Application made on the 25 September - 150 days up on the 22 February, with the company providing a sensible cushion of expectation going into Q2.

Watch this space

MAJOR EUROPEAN CONSORTIUM

Just waiting for the Major Pharma Contract which is due shortly and is outlined in the YouTube video last night. Expect another RNS

Question is, was today’s presentation released on YouTube (confidential @ bottom of presentation), after the markets closed part of an update tomorrow and further comments on the earlier shared article, or a bit of unprompted promo ??

https://youtu.be/p8_o-8QZP_I

Closed at 82p UT

https://www.nature.com/articles/s41598-021-82068-9.pdf

Perhaps one of the reasons why the company mentioned a large Pharma services contact soon and an earlier webinar implied the first contract would be PD-L1

Not to just take the multi billion dollar valuation gap into consideration but the 5 key strategic objectives that are to come to fruition over the next 6 months, many of which target multi billion dollar emerging revenue streams.

We know news drives share prices and as per the presentations, partnership discussions, parsortix upgrade, ovarian cancer study completion and conversion to lab based test ($b market), proof of concept, labs, fda approval and a highly differentiated solution that provides competitive advantages over its peers.

A massive PLATFORM to growth. All for less than £180m. A trajectory like ITM has been on from its lower levels is not inconceivable.

Take out 85p and it will very quickly exceed 100p imo.

So far Iv heard that on various forums including social media. In the 50/60 and now 70’s and in all probability the same will be said when this is over 100p.

In all honesty, every pull back has been bought into and at some point we will see some more consolidation, but when the market cap is still only £167m, you only needs to look to it’s peers and the multi multi billion pound opportunity ahead.

Imagine what a partnering agreement would do to the share price!

For what its worth, and obvious to some, a significant market cap of 3/4/500m would assist a Nasdaq listing which would take this to a new level altogether. All of which is coming and more!

Isn’t truly reflecting the strength here (yet).

Would not be surprised to see breakout

Hooray, but no different to the other 29 approvals in the in vitro category who also found themselves in exactly the same position.

Persimmon - I think de novo has to be remembered for what it is:

The De Novo process provides a pathway to classify novel medical devices for which general controls alone, or general and special controls, provide reasonable assurance of safety and effectiveness for the intended use, but for which there is no legally marketed predicate device.

‘No legally marketed predicative device’, making the Q submission inherently valuable in this process to further manage the outcome and avoid withdrawal in an attempt to seek additional information such as clinical frials

We are class II of III which further derisks the proposition and therefore time imo.

Everyone is entitled to an opinion both positive and negative as I am trying/actively to identify the risks.